Open label, uncontrolled, pilot, phase II study of histone-deacetylase inhibitor ITF2357 administered orally to subjects with chronic lynphocytic leukemia (CLL) refractory/relapsed after conventional chemotherapy or relapsed after autologous bone marrow transplantation Rate of complete or partial response in all patients

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Long-term study evaluating the effect of Givinostat in cMPN. Studio a lungo termine volto alla valutazione dell'effetto di Givinostat nelle sindromi mieloproliferative croniche - To determine the long term safety and tolerability of Givinostat in patients with cMPN following core protocols or compassionate use program; - To obtain information on the long term efficacy of G...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin’s Lymphoma Patients To evaluate the anti-lymphoma efficacy of daily oral doses of ITF2357 folllowed by intravenous Mechlorethamine administered to patients with refractory/relapsed Hodgkin’s lymphoma

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Paroxetine drops for the switch-therapy in patients chronic users of Benzodiazepines: an experience in Community Medicine To study the advantages derived from an SSRI added to the educational program of gradual benzodiazepines tapering in a clinical practical context.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase II Multiple-Dose Clinical Trial of Oral ITF 2357 In Patients with Advanced Multiple Myeloma

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para determinar la eficacia y seguridad de una nueva formulación de estriol en baja concentración (ITFE-2026 0,005%) para aplicación vía vaginal en el tratamiento de la atrofia vaginal postmenopáusica EVALUAR LA EFICACIA DE ITFE-2026 0.005% MEDIANTE EL CAMBIO EN EL VALOR DE MADURACION (VM) TRAS 12 SEMANAS

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase II study of the histone-deacetylase inhibitor GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responder to hydroxyurea monotherapy Studio di fase II con l inibitore dell istone deacetilasi GIVINOSTAT (ITF2357) in associazione con Idrossiurea in pazienti affetti da Policitemia Vera JAK2V617F positivi, che non hanno risposto al trattamento in monoterapia con Idrossiurea To evaluate the efficacy of GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responders to the maximum tolerated dose of hydroxyurea monot...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase IIA study of the histone-deacetylase inhibitor ITF2357 in patients with JAK-2 V617F positive chronic myeloproliferative diseases To evaluate efficacy and safety of ITF 2357 in the treatment of patients with JAK2 V617F positive myeloproliferative diseases (PV, ET, MF). Efficacy will be evaluated by ad hoc haematological and clin...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Chronic iloprost administration in scleroderma patients effect on disease progression, as assessed by skin fibrosis evaluation. A randomized, controlled, blind-observer, multicenter phase III study

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children with Duchenne Muscular Dystrophy Studio diviso in due parti per valutare la sicurezza e la tollerabilita’, la farmacocinetica, e gli effetti sull’istologia e i diversi paramentri clinici di Givinostat in bambini deambulanti affetti da distrofia muscolare di Duchenne To establish the histologic effects of Givinostat administered chronically at the selected daily dose Stabilire gli effetti istologici di Givinostat somministrato in modo cronico alla dose giorn...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune